Barclays PLC Purchases 112,614 Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX)

Barclays PLC grew its holdings in shares of Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) by 195.4% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 170,245 shares of the company's stock after buying an additional 112,614 shares during the period. Barclays PLC owned 0.12% of Compass Therapeutics worth $314,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Geode Capital Management LLC increased its stake in shares of Compass Therapeutics by 0.8% during the third quarter. Geode Capital Management LLC now owns 2,309,778 shares of the company's stock valued at $4,251,000 after buying an additional 19,095 shares during the period. Renaissance Technologies LLC increased its stake in shares of Compass Therapeutics by 99.7% during the second quarter. Renaissance Technologies LLC now owns 140,600 shares of the company's stock valued at $141,000 after buying an additional 70,200 shares during the period. Rhumbline Advisers increased its stake in shares of Compass Therapeutics by 10.3% during the second quarter. Rhumbline Advisers now owns 131,789 shares of the company's stock valued at $132,000 after buying an additional 12,315 shares during the period. The Manufacturers Life Insurance Company purchased a new position in shares of Compass Therapeutics during the third quarter valued at approximately $79,000. Finally, Cubist Systematic Strategies LLC purchased a new position in shares of Compass Therapeutics during the second quarter valued at approximately $41,000. 68.43% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

CMPX has been the topic of several research analyst reports. Leerink Partners cut Compass Therapeutics from an "outperform" rating to a "market perform" rating and reduced their target price for the company from $5.00 to $4.00 in a research note on Friday, November 15th. D. Boral Capital reaffirmed a "buy" rating and issued a $32.00 price target on shares of Compass Therapeutics in a research note on Wednesday, January 8th. HC Wainwright reaffirmed a "buy" rating and issued a $10.00 price target on shares of Compass Therapeutics in a research note on Wednesday, January 8th. Finally, Leerink Partnrs cut Compass Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Friday, November 15th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $11.80.

Compass Therapeutics Trading Up 4.0 %

Compass Therapeutics stock traded up $0.10 during mid-day trading on Monday, hitting $2.60. The company had a trading volume of 1,402,133 shares, compared to its average volume of 1,506,824. The stock's 50 day moving average price is $1.62 and its two-hundred day moving average price is $1.50. Compass Therapeutics, Inc. has a 12 month low of $0.76 and a 12 month high of $2.70. The company has a market capitalization of $357.73 million, a PE ratio of -7.03 and a beta of 0.92.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.11) by $0.03. Equities research analysts anticipate that Compass Therapeutics, Inc. will post -0.35 EPS for the current year.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.